NCT01470287View on ClinicalTrials.gov

Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
DiphtheriaTetanusPertussisHepatitis BHemophilus Influenzae B
Interventions
BIOLOGICAL

DTwP-HepB-Hib Vaccine

Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.

Trial Locations (3)

Unknown

Rajarajeshwari Medical College and Hospital, Bangalore

Bharathi Vidyapeeth University, Pune

Medical College Kolkata, Kolkata

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY